Genes & CellsGenes & CellsГены и КлеткиGenes and Cells2313-18292500-2562Human Stem Cells Institute12240210.23868/gc122402ReviewsНаучные обзорыReview ArticleCell technologies in the treatmemt of critical lower limbs ischemiaКлеточные технологии в лечении терминальной стадии хронической ишемии нижних конечностейSmolyaninovA. B.СмоляниновА. Б.
Russian Federation
info@eco-vector.comPykhtinE. V.ПыхтинЕ. В.
Russian Federation
info@eco-vector.comBulginD. V.БулгинД. В.
Russian Federation
info@eco-vector.comTomonagaM.ТомонагаМ.
Japan
info@eco-vector.comCenter of Cell and Gene Therapy, Stem cell Bank «POKROVSKI»Центр клеточной и генной терапии, Покровский банк стволовых клетокNagasaki UniversityУниверситет Нагасаки150920072340461601202316012023Copyright ©; 2007, Eco-VectorCopyright ©; 2007, Эко-Вектор2007Eco-VectorЭко-Векторhttps://genescells.ru/2313-1829/article/view/122402

This article presents reviews application of cell technologies in the treatment of critical limb ischemia. Surgery treatment remains a basic method in the treatment of vascular obliterans limb diseases. In our days surgical methods are known as the most effective treatment of main artery atherosclerosis, but this kind of treatment is not so good for treatment peripheral arterial diseases such as thromboangitis obliterans (Buerger’s disease) because of often restenosis and rethrombosis development. Principal purpose efforts of surgeons according on ensuring of adequate blood flow in terminal parts of limb and also on support effective perfusion of tissue. This aim could be obtain due to undirected revascularization. Recently thanks to development of cells technologies on a level with osteothrepanation and lumbal sympathectomy it became possible to create new ways of roundabout blood flow in ischemic limb. Autological stem cells transplantation to patients with critical ischemic limb provides an appearance of new sites revascularization. In last years experimental and clinical studies in this area confirm safety and efficiency of the stem cells transplantation to patients with ischemic limb disease. However, few questions about quality and quantity of stem cells which are necessary for appearance revascularization remain unknown.

В статье представлен обзор вариантов применения клеточных технологий в лечении терминальной стадии хронической ишемии нижних конечностей. Основным методом лечения сосудистых заболеваний нижних конечностей остается хирургическое вмешательство. Высокая эффективность применения хирургического метода, достигается при поражении магистральных артерий, в то же время, при поражении дистальных сегментов периферических артерий (облитерирующий эндартериит и тромбангиит - болезнь Бюргера) оперативное лечение мало эффективно вследствие повторного образования тромбов и последующего стенозирования. Основные усилия хирургов при лечении таких заболеваний направлены на обеспечение адекватного притока крови к дистальным отделам конечности и поддержания эффективной перфузии тканей. Этого можно достичь путем непрямой реваскуляризации. Помимо традиционных методов лечения, таких как остеотрепанация и поясничная симпатэктомия, в последнее время активно изучается возможность применения клеточных технологий для создания новых путей коллатерального кровообращения в конечности. Трансплантация больному его собственных стволовых клеток стимулирует ангиогенез в ишемизированных тканях. Проведенные экспериментальные и клинические исследования в этой области подтверждают высокую эффективность и безопасность трансплантации стволовых клеток больным с данной патологией. Однако есть неразрешенные вопросы, касающиеся «качества» и количества клеток, необходимых для образования новых сосудов.

critical limb ischemiastem cells transplantationbone morrowendothelial progenitorsтерминальная стадия хронической ишемии нижних конечностейтрансплантация стволовых клетоккостный мозгпредшественники эндотелиоцитовСавельев В.С., Кошкин В.М. Критическая ишемия нижних конечностей. М.: Медицина; 1997.Second European Consensus Document on chronic critical leg ischemia. Circ. 1999; 84(IV): 1-26.Dormandly J.A., Rotherford R.B. Management of peripheral arterial disease. TASC Group. Trans Atlantic Inter-Society Consensus. J. Vasc. Surg. 2000; 31: 1-296.Смолянинов А.Б. Современные биотехнологические центры клеточных и генных технологий и банки стволовых клеток. Технология чистоты 2006; 1: 4-5.Смолянинов А.Б., Жарова Е.В., Козлова К.Л., Кириллова Д.А. Основы клеточной и генной терапии сердечно-сосудистых заболеваний. М.; 2005.Baumgartner I., Schainfeld R., Graziani L. Management of peripheral vascular disease. An. Rev. Med. 2005; 56: 249-72.Vascular Society of Great Britain and Ireland. B. J. Surg. 2007; 94: issue 2: 1-13.Emmerich J. Current state and perspective on medical treatment of critical leg ischemia: Gene and cell therapy. Int. J. of Lower Extremity Wounds 2005; 4: 234-41.Dorros G., Jaff M.R., Dorros A.M. et al. Tibioperoneal (outflow lesion) angioplasty can be used as primary treatment in 235 patients with critical limb ischemia: five-year follow-up. Circ. 2001; 104: 2057-62.Kudo T., Chandra F.A., Ahn S.S. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J. Vasc. Surg. 2005; 41: 423-35.Faglia E., Dalla Paola L., Clerici G. et al. Peripheral angioplasty as the first- choice revascularization procedure in diabetic patients with critical limb ischemia prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur. J. Vasc. Endovasc. Surg. 2005; 29: 620-7.Leng G.C., Davis M., Baker D. Bypass surgery for chronic lower limb ischemia. Cochrane Database Syst. Rev. 2000; CD 0020000.Бураковский В.И., Бокерия Л.А. Сердечно-сосудистая хирургия. М.: Медицина; 1989.Schainfeld R.M., Isner J.M. Critical limb ischemia: nothing to give at the office? An. Intern. Med. 1999; 130: 442-4.Казьмин З.В. Комплексное хирургическое и консервативное лечение хронической критической ишемии при отсутствии условий прямой реваскуляризации нижних конечностей. Автореф. дисс.... канд. мед. наук. М., 2006.Gavrilenko A.V. Current possibilities of the reconstructive vascular surgery and the outlooks for using genetic engineering in critical ischemia of the lower extremities. Vestn. Ross. Akad. Med. Nauk 2003; (12): 74-7.Nishikawa S.I., Nishikawa S., Hirashima M. et al. Progressive lineage analysis by cell sorting and culture identifies FLK+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages. Dev. 1998; 125: 1747-57.Gehling U.M., Ergun S., Schumacher U. et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000; 95: 3106-12.Asahara T., Murohara T., Sullivan A. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995; 1: 27-31.Asahara T., Masuda H., Takahashi T. et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 1999; 85: 221-8.Reyes M., Dudek A., Jahagirdar B. et al. Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 2002; 109: 337-46.Isner J.M., Pieczek A., Schainfeld R. et al. Clinical evidence of angio-genesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-4.Pearlman J.D., Hibberd M.G., Chuang M.L. et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat. Med. 1995; 1: 1085-9.Baumgartner I., Pieczek A., Manor O. et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circ. 1998; 97: 1114-23.Folkman J. Therapeutic angiogenesis in ischemic limbs. Circ. 1998; 97: 1108-10.Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorogenesis. Cell 1996; 86: 353-64.Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.Yancopoulos G.D., Davis S., Gale N.W. et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.Pepper M.S. Manipulating angiogenesis. From basic science to the bedside. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 605-19.Majka S.M., Jackson K.A., Kienstra K.A. et al. Distinct progenitor populations in skeletal muscle are bone marrow derived and exhibit different cell fates during vascular regeneration. J. Clin. Invest. 2000; 111: 71-9.Asahara T., Masuda H., Takahashi T. et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 1999; 85: 221-8.Asahara T., Takahashi T., Masuda H. et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999; 18: 3964-72.Iwaguro H., Yamaguchi J., Kalka C. et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circ. 2002; 105: 732-8.Kalka C., Masuda H., Takahashi T. et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. USA 2002; 97: 3422-7.Schatteman G.C., Hanlon H.D., Jiao, C. et al. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J. Clin. Invest. 2000; 106: 571-8.Crosby J.R., Kaminski W.E., Schatteman G. et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ. Res. 2000; 87: 728-30.Takahashi T., Kalka C., Masuda H. et al. Ischemia- and cytokine-induced mo-bilization of bone marrow-derived endothelial progenitor cells for neovasculariza-tion. Nat. Med. 1999; 5: 434-8.Luttun A., Carmeliet G., Carmeliet, P. Vascular progenitors: from biology to treatment. Trends Cardiovasc. Med. 2002; 12: 88-96.Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 2000; 105: 17-9.Shi Q., Rafii S., Wu M.H. et al. Evidence for circulating bone marrow- derived endothelial cells. Blood 1998; 92: 362-7.Bhattacharya V., McSweeney P.A., Shi Q. et al. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34+ bone mar-row cells. Blood 2000; 95: 581-5.Kaushal S., Amiel G.E., Guleserian K.J. et al. Functional small-diameter neovessels created using endothelial progenitr cells expanded ex vivo. Nat. Med. 2001; 7: 1035-40.Noishiki Y., Tomizawa Y., Yamane Y., Matsumoto A. Autocrine angio-genic vascular prosthesis with bone marrow transplantation. Nat. Med. 1996; 2: 90-3.Sata M., Saiura A., Kunisato A. et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med. 2002; 8: 403-9.Young P.P., Höfling A.A., Sands M.S. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of new-born murine recipients. Proc. Natl. Acad. Sci. USA 2002; 99: 11951 -6.Lyden D., Hattori K., Dias S. et al. Impaired recruitment of bone-marrow- derived endothelial and hematopoietic precursor cells blocks tumor angio-genesis and growth. Nat. Med. 2001; 7: 1194-201.Moore M.A. Putting the neo into neoangiogenesis. J. Clin. Invest. 2002; 109: 313-5.Gehling U.M., Ergun S., Schumacher U. et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000; 95: 3106-12.Marchetti S., Gimond C., Iljin K. et al. Endothelial cells genetically selected from differentiating mouse embryonic stem cells incorporate at sites of neovascularization in vivo. J. Cell. Sci. 2002; 115: 2075-85.Davidoff A.M., Ng C.Y., Brown P. et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res. 2001 ; 7: 2870-9.Isner J.M. Myocardial gene therapy. Nature 2002; 415: 234-9.Khurana R., Simons M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc. Med. 2003; 13: 116-22.Cao R., Brakenhielm E., Pawliuk R. et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 2003; 9: 604-13.Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angiomagenesis? Nat. Med. 2000; 6: 1102-3.Kim S., Han H., Chae G. et al. Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model. Stem Cells 2006; 9(4): 1128-34.Shintani S., Murohara T., Ikeda H. et al. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circ. 2001; 103: 897-908.Finney M.R., Greco N.J., Haynesworth S.E. et al. Direct comparison of umbilical cord blood versus bone marrow-derived endothelial precursor cells in mediating neovascularization in response to vascular ischemia. Biol. Blood Marrow Transpl. 2006; 12(5): 585-93.Kim D., Kim M., Joh J. Angiogenesis facilitated by autologous whole bone marrow stem cell transplantation for Buerger's disease. Stem Cells 2006; 24(5): 1194-200.Schatteman G.C., Dunnwald M., Jiao C. et al. Biology of bone marrow-derived endothelial cell precursors. Am. J. Physiol. Heart Circ. Physiol. 2007; 292: 1-18.Kinnaird T., Stabile E., Burnett M.S., Epstein S.E. Bone marrow-derived cells for enhancing collateral development: Mechanisms, animal data, and initial clinical experiences. Circ. Res. 2004; 95: 354-62.Miyamoto K., Kondo T., Suzuki S. et al. Molecular evaluation of endothelial progenitor patients with ischemic limbs. Ather. Thromb. and Vasc. Biology 2004; 24: 192-202.Schatteman G.C., Dunnwald M., Jiao C. Biology of bone marrow-derived endothelial cell precursors. Am. J. Physiol. Heart. Circ. Physiol. 2007; 292(1): 1-18.Shi Q., Bhattacharya V., Hong-De Wu M., Sauvage, L.R. Utilizing granulocyte colonystimulating factor to enhance vascular graft endothelialization from circulating blood cells. Ann. Vasc. Surg. 2002; 16: 314-20.Jiang Y., Jahagirdar B.N., Reinhardt R.L. et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-9.Tateishi-Yuyama E., Matsubara H., Murohara T. et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: a pilot study and randomized controlled trial. Lancet 2002; 360: 427-35.Higashi Y., Kimura M., Hara K. Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilatation in patients with limb ischemia. Circ. 2004; 109: 1215-18.Saigawa T., Kato K., Ozawa T. et al. Clinical application of bone-marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone-marrow cells. Circ. J. 2004; 68: 1189-93.Iba O., Matsubara H., Nozawa Y. et al. Angiogenesis is by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circ. 2002; 106: 2019-25.Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat. Med. 2002; 8: 1249-56.Ribatti D., Vacca A., Roncali L., Dammacco, F. Hematopoiesis and angiogenesis: a link between two apparently independent processes. J. Hematother. Stem Cell Res. 2000; 9: 13-9.Hattori K., Dias S., Heissig B. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 2001 ; 93: 1005-14.Al-Khaldi A., Al-Sabti H., Galipeau J., Lachapelle K. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model // Ann. Thorac. Surg. 2003; 75(1): 204-9.Pesce M., Orlandi A., Iachininoto M.G. et al. Myoendothelial Differentiation of Human Umbilical Cord Blood-Derived Stem Cells in Ischemic Limb Tissues. Circ. Res. 2003; 93: e51-62.Nakagami H., Maeda K., Morishita R. Novel autologous cell Therapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells. Arterioscler. Thromb. and Vasc. Biol. 2005; 25: 25-42.Esato K., Hamano K., Li T.S. et al. Neovascularization induced by autologous bone cells implantation in peripheral arterial disease. Cell Transpl. 2002; 11(8): 747-52.Huang P.P., Li S.Z., Han M.Z. et al. Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. Thromb. Haemost. 2004; 91: 606-9.Van Royen N., Schirmer S.H., Atasever B. et al. START Trial: a pilot study on stimulation of arteriogenesis using subcutaneous application of granulocyte-macrophage-colony-stimulating factor as a new treatment for peripheral vascular disease. Circ. 2005; 112: 1040-49.Miyamoto K., Nishigami K., Nagaya N. et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclears in patients with thromboangiitis obliterans. Circ. 2006; 114: 2679-84.Yoon Y.S., Murayama T., Gravereaux E. et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J. Clin. Invest. 2003; 111: 717-25.Saaristo A., Karkkainen M.J., Alitalo K. Insights into the molecular pathogenesis and targeted treatment of lymphedema. An. NY Acad. Sci. 2002; 979: 94-110.Szuba A., Skobe M., Karkkainen M.J. et al. Therapeutic lymphangiogenesis with human recombinant VEGF. C. FASEB J. 2002; 16: 1985-87.Sata M., Saiura A., Kunisato A. et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med. 2002; 8: 403-9.Caplice N.M., Bunch T.J., Stalboerger P.G. et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc. Natl. Acad. Sci. USA 2003; 100: 4754-59.Hill J.M., Zalos G., Halcox J.P. et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 2003; 348: 593-600.Hillebrands J.L., Klatter F.A., van Dijk W.D., Rozing J. Bone marrow does not contribute substantially to endothelial-cell replacement in transplant arteriosclerosis. Nat. Med. 2002; 8: 194-5.Wagers A.J., Sherwood R.I.., Christensen J.L., Weissman I.L. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 2002; 297: 2256-59.Rehman J., Li J., Orschell C.M., March K.L. Peripheral blood endothelial progenitor cells are derived from monocyte/macrophages and secrete angiogenic growth factors. Circ. 2003; 107: 1164-69.Solovey A.N., Gui L., Chang L. et al. Identification and functional assessment of endothelial P1H12. J. Lab. Clin. Med. 2001 ; 138: 322-31.Peichev M., Naiyer A.J., Pereira D. et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952-8.Hillebrands J.L., Klatter F.A., Rozing J. Origin of vascular smooth muscle cells and the role of circulating stem cells in transplant arteriosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 380-7.Shimizu K., Sugiyama S., Aikawa M.et al. Host bone-marrow cells are a source of donor intimal smoothmusclelike cells in murine aortic transplant arteriopathy. Nat. Med. 2001; 7: 738-41.Hu Y. Davison F., Ludewig B. et al. Smooth muscle cells in transplant atherosclerotic lesions are originated from recipients, but not bone marrow progenitor cells. Circ. 2002; 106: 1834-9.Noishiki Y., Tomizawa Y., Yamane Y., Matsumoto A. Autocrine angiogenic vascular prosthesis with bone marrow transplantation. Nat. Med. 1996; 2: 90-3.Celletti F.L., Waugh J.M., Amabile P.G. et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med. 2001; 1: 425-9.Van Royen N., Hoefer I., Bottinger M. et al. Local monocyte chemoattractant protein-1 therapy in-creases collateral artery formation in apolipoprotein Edeficient mice but in-duces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ. Res. 2003; 92: 218-25.Gill M., Dias S., Hattori K. et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+) AC133(+) endothelial precursor cells. Circ. Res. 2001; 88: 167-74.Vasa M., Fichtlscherer S., Adler K. et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circ. 2001; 103: 2885-90.Shintani S., Murohara T., Ikeda H. et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circ. 2001; 103: 2776-79.Murasawa S., Llevadot J., Silver M.et al. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circ. 2002; 106: 1133-9.